Cost-effectiveness of golimumab for the treatment of patients with moderate-to-severe ulcerative colitis in Quebec using a patient level state transition microsimulation

References

• Stange EF, Travis SP, Vermeire S, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008;2:1-23
   PubMed Web of Science ®Google Scholar
• Targownik LE, Singh H, Nugent Z, et al. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol 2012;107:1228-35
   PubMed Web of Science ®Google Scholar
• Rocchi A, Benchimol EI, Bernstein CN, et al. Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol 2012;26:811-17
   PubMed Web of Science ®Google Scholar
• Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology 2015;148:1035-58 e3
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780-7
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:85-95; quiz e14–15
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:96-109 e1
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-65 e1–3
   PubMed Web of Science ®Google Scholar
• Archer R, Tappenden P, Ren S, et al. Infliximab; adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technol Assess 2016;20:1-326
   Web of Science ®Google Scholar
• Stawowczyk E, Kawalec P, Pilc A. Cost-effectiveness analysis of 1-year treatment with golimumab/standard care and standard care alone for ulcerative colitis in Poland. PLoS One 2016;11:e0160444
   PubMed Web of Science ®Google Scholar
• Tappenden P, Ren S, Archer R, et al. A model-based economic evaluation of biologic and non-biologic options for the treatment of adults with moderately-to-severely active ulcerative colitis after the failure of conventional therapy. Pharmacoeconomics 2016;34:1023-38
   PubMed Web of Science ®Google Scholar
• Toor K, Druyts E, Jansen JP, et al. Cost per remission and cost per response with infliximab; adalimumab; and golimumab for the treatment of moderately-to-severely active ulcerative colitis. J Med Econ 2015;18:437-46
   PubMed Web of Science ®Google Scholar
• Ung V, Thanh NX, Wong K, et al. Real-life treatment paradigms show infliximab is cost-effective for management of ulcerative colitis. Clin Gastroenterol Hepatol 2014;12:1871-8 e8
   PubMed Web of Science ®Google Scholar
• Xie F, Blackhouse G, Assasi N, et al. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost Eff Resour Alloc 2009;7:20
   PubMedGoogle Scholar
• Archer R, Tappenden P, Ren S, et al. Infliximab; adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy. Technology Assessment Report: Final report to the National Institute for Health and Care Excellence. Sheffield; UK: University of Sheffield; 2014
   Google Scholar
• Gibson PR, Feagan BG, Sandborn WJ, et al. Maintenance of efficacy and continuing safety of golimumab for active ulcerative colitis: PURSUIT-SC maintenance study extension through 1 year. Clin Transl Gastroenterol 2016;7:e168
   PubMed Web of Science ®Google Scholar
• Bitton A, Buie D, Enns R, et al. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol 2012;107:179-94; author reply 95
   PubMed Web of Science ®Google Scholar
• Woehl A, Hawthorn AB, Morgan CL, et al. The epidemiology and healthcare resource use in patients with ulcerative colitis: a population-based UK study. Value Health 2007;Abstract A355–A6
   Web of Science ®Google Scholar
• Arseneau KO, Sultan S, Provenzale DT, et al. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? Clin Gastroenterol Hepatol 2006;4:1135-42
   PubMed Web of Science ®Google Scholar
• Thorlund K, Druyts E, Toor K, et al. Comparative efficacy of golimumab; infliximab; and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs. Expert Rev Gastroenterol Hepatol 2015;9:693-700
   PubMed Web of Science ®Google Scholar
• Human Mortality Database; Canada; Life Tables (Period: 1x1; age interval x year interval) [Internet]. Last modified: 11 August 2014 [Internet]. University of California; Berkeley (US) and Max Planck Institute for Demographic Research (Germany); 2014. http://www.mortality.org/cgi-bin/hmd/country.php?cntr=CAN&level =1
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the Economic Evaluation of Health Technologies: Canada, 3rd Edition. Ottawa: Canadian Agency for Drugs and Technologies in Health; March 2006. https://www.cadth.ca/sites/default/files/pdf/186_EconomicGuidelines_e.pdf
   Google Scholar
• Swinburn P, Elwick H, Bean K, et al. The impact of surgery on health related quality of life in ulcerative colitis. Poster PTU-127 at the Digestive Disorders Federation Meeting; 17–20 June 2012; Liverpool UK. Gut 2012;61:A237
   Google Scholar
• van der Valk ME, Mangen MJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study. Gut 2014;63:72-9
   PubMed Web of Science ®Google Scholar
• Crohn’s and Colitis Foundation of Canada. The impact of inflammatory bowel disease in Canada: 2012 final report and recommendations. Toronto: Crohn’s and Colitis Foundation of Canada; November 2012. http://www.isupportibd.ca/pdf/ccfc-ibd-impact-report-2012.pdf
   Google Scholar
• Busch K, da Silva SA, Holton M, et al. Sick leave and disability pension in inflammatory bowel disease: a systematic review. J Crohns Colitis 2014;8:1362-77
   PubMed Web of Science ®Google Scholar
• Cohen RD, Yu AP, Wu EQ, et al. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther 2010;31:693-707
   PubMed Web of Science ®Google Scholar
• Fedorak RN, Wong K, Bridges R. Canadian Digestive Health Foundation Public Impact Series. Inflammatory bowel disease in Canada: Incidence; prevalence; and direct and indirect economic impact. Can J Gastroenterol 2010;24:651-5
   PubMed Web of Science ®Google Scholar
• Longobardi T, Jacobs P, Wu L, et al. Work losses related to inflammatory bowel disease in Canada: results from a National Population Health Survey. Am J Gastroenterol 2003;98:844-9
   PubMed Web of Science ®Google Scholar
• Neovius M, Arkema EV, Blomqvist P, et al. Patients with ulcerative colitis miss more days of work than the general population; even following colectomy. Gastroenterology 2013;144:536-43
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Bala M, et al. Response and remission are associated with improved quality of life; employment and disability status; hours worked; and productivity of patients with ulcerative colitis. Inflamm Bowel Dis 2007;13:1135-40
   PubMed Web of Science ®Google Scholar
• Tsai HH,Punekar YS, Morris J, et al. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther 2008;28:1230-9
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Infliximab; adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy. Technology appraisal guidance 329 [TA329]. Chapter 4. Evidence and Interpretation London: NICE; 2015. https://www.nice.org.uk/guidance/ta329/chapter/4-Evidence-and-interpretation
   Google Scholar
• Mei WQ, Hu HZ, Liu Y, et al. Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis. World J Gastroenterol 2015;21:6044-51
   PubMed Web of Science ®Google Scholar
• Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther 2014;39:660-71
   PubMed Web of Science ®Google Scholar
• Ferrante M, Vermeire S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2008;2:219-25
   PubMed Web of Science ®Google Scholar
• RAMQ. Liste de Médicaments; Edition 52. Québec: Régie de l’assurance maladie du Québec (RAMQ); October 2014. http://www.ramq.gouv.qc.ca/fr/professionnels/pharmaciens/Pages/pharmaciens.aspx
   Google Scholar
• RAMQ. Manuel des services de laboratoire en établissement du Québec. MAJ 64. Québec: Régie de l’assurance maladie du Québec (RAMQ); November 2014. http://www.ramq.gouv.qc.ca/fr/professionnels/medecins-specialistes/manuels/Pages/sle.aspx
   Google Scholar
• RAMQ. Manuel de facturation des médecins omnipraticiens. Quebec: Régie de l’assurance maladie du Québec (RAMQ); January 2014. http://www.ramq.gouv.qc.ca/SiteCollectionDocuments/professionnels/manuels/100-facturation-omnipraticiens/maj79_acte_omni.pdf
   Google Scholar
• Conseil du médicament-Québec. Community-acquired pneumonia in adults: general information; diagnosis; treatment guidelines. Québec: Conseil du médicament; 2009. http://www.inesss.qc.ca/fileadmin/doc/CDM/UsageOptimal/Guides-serieI/CdM-Antibio1-Pneumonia-Adults-eng.pdf
   Google Scholar
• Patient cost estimator; average cost for hospital stay by CMG code for Quebec; CMG codes: 136 and 138; fiscal year 2010–11 [Internet]. Canadian Institute for Health Information; 2014. http://www.cihi.ca/CIHI-ext-portal/internet/EN/ApplicationIndex/applicationindex/applications_index_main#
   Google Scholar
• Croft A, Walsh A, Doecke J, et al. Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. Aliment Pharmacol Ther 2013;38:294-302
   PubMed Web of Science ®Google Scholar
• Penna C, Dozois R, Tremaine W, et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996;38:234-9
   PubMed Web of Science ®Google Scholar